Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Miniature Device to Transform Testing of Blood Cancer Treatments

By LabMedica International staff writers
Posted on 02 Jul 2025

Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for blood cancers like leukemia, offering hope to patients when other treatments fail. More...

However, despite its promise, nearly half of leukemia patients relapse, and many suffer from serious side effects. Efforts to improve CAR T therapies have been hampered by the limitations of conventional testing methods. Traditional models fail to accurately replicate the complex human immune response and the bone marrow environment where leukemia develops. Now, researchers have developed a new solution to bridge this gap—a platform that allows for real-time observation of cancer treatment interactions under controlled conditions, offering a more accurate and patient-specific approach to testing blood cancer therapies.

This innovative platform, termed “leukemia-on-a-chip,” was developed through a collaboration between the Perelman School of Medicine at the University of Pennsylvania (Philadelphia, PA, USA) and the Tandon School of Engineering at New York University (Brooklyn, NY, USA). The device is the first to successfully recreate the physical and immunological environment of human bone marrow on a microscope slide-sized chip. It integrates three distinct bone marrow regions—blood vessels, surrounding marrow cavity, and the outer bone lining—and when seeded with patient-derived cells, it self-organizes to produce structural proteins such as collagen, fibronectin, and laminin. Importantly, the device preserves the immune cell activity within the marrow microenvironment. The system incorporates vascular networks to simulate realistic immune interactions in three dimensions, providing a level of insight and accuracy far beyond 2D cultures or animal models. The development is also timely, coinciding with the FDA’s new roadmap to reduce animal testing requirements in drug development.

In their study published in Nature Biomedical Engineering, the researchers used advanced imaging to watch CAR T cells move through blood vessels, detect cancer cells, and destroy them—processes previously impossible to view with this clarity. They observed that engineered immune cells not only targeted leukemia cells but also activated other immune cells nearby in a “bystander effect” that may explain both therapeutic success and some side effects. The team simulated different patient responses, including remission, relapse, and resistance, and demonstrated that newer, fourth-generation CAR T cells performed better than standard versions, even at lower doses. The chip setup takes just half a day to assemble and supports experiments for up to two weeks, in contrast to animal models that require months. Going forward, the researchers aim to use this platform to test individual patient cancer cells against various treatment designs, enabling a personalized approach to therapy selection before treatment begins.

Related Links:
Perelman School of Medicine
Tandon School of Engineering


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.